JP2017512799A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512799A5
JP2017512799A5 JP2016559300A JP2016559300A JP2017512799A5 JP 2017512799 A5 JP2017512799 A5 JP 2017512799A5 JP 2016559300 A JP2016559300 A JP 2016559300A JP 2016559300 A JP2016559300 A JP 2016559300A JP 2017512799 A5 JP2017512799 A5 JP 2017512799A5
Authority
JP
Japan
Prior art keywords
composition
seq
peptide
dwgpk
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512799A (ja
JP6727129B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022745 external-priority patent/WO2015148801A1/en
Publication of JP2017512799A publication Critical patent/JP2017512799A/ja
Publication of JP2017512799A5 publication Critical patent/JP2017512799A5/ja
Application granted granted Critical
Publication of JP6727129B2 publication Critical patent/JP6727129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559300A 2014-03-26 2015-03-26 環状プロサポシンペプチドおよびその使用 Active JP6727129B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970853P 2014-03-26 2014-03-26
US61/970,853 2014-03-26
PCT/US2015/022745 WO2015148801A1 (en) 2014-03-26 2015-03-26 Cyclic prosaposin peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020029398A Division JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2017512799A JP2017512799A (ja) 2017-05-25
JP2017512799A5 true JP2017512799A5 (enExample) 2018-05-24
JP6727129B2 JP6727129B2 (ja) 2020-07-22

Family

ID=54196396

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016559300A Active JP6727129B2 (ja) 2014-03-26 2015-03-26 環状プロサポシンペプチドおよびその使用
JP2020029398A Active JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用
JP2023010162A Pending JP2023053978A (ja) 2014-03-26 2023-01-26 環状プロサポシンペプチドおよびその使用
JP2024170459A Pending JP2025010144A (ja) 2014-03-26 2024-09-30 環状プロサポシンペプチドおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020029398A Active JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用
JP2023010162A Pending JP2023053978A (ja) 2014-03-26 2023-01-26 環状プロサポシンペプチドおよびその使用
JP2024170459A Pending JP2025010144A (ja) 2014-03-26 2024-09-30 環状プロサポシンペプチドおよびその使用

Country Status (6)

Country Link
US (5) US10646541B2 (enExample)
EP (2) EP3122369B1 (enExample)
JP (4) JP6727129B2 (enExample)
CN (2) CN113908253A (enExample)
AU (4) AU2015235978B2 (enExample)
WO (1) WO2015148801A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3127549B1 (en) 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
US10646541B2 (en) * 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4449125A4 (en) * 2021-12-17 2026-01-28 Vigeo Therapeutics Inc CANCER TREATMENT METHODS AND COMPOSITIONS

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
GB8518144D0 (en) 1985-07-18 1985-08-21 Univ Belfast Solid phase peptide synthesis
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4794150A (en) 1987-03-11 1988-12-27 Samuel Steel Synthesis of peptide analogs
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5180816A (en) 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5221754A (en) 1989-06-09 1993-06-22 Research Corporation Technologies, Inc. Reagents for rapid peptide synthesis
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5552471A (en) 1994-08-17 1996-09-03 The Perkin-Elmer Corporation Solid support reagents for the synthesis of 3'-Nitrogen containing polynucleotides
US6001966A (en) 1995-10-19 1999-12-14 Proligo Llc Method for solution phase synthesis of oligonucleotides and peptides
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
JP2001515866A (ja) 1997-09-09 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロサポシン受容体アゴニストを利用したアポトーシスの阻害
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US7094943B2 (en) 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6500431B1 (en) 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US6706252B1 (en) 1998-10-30 2004-03-16 Rx/Ibr Corporation Method of treating disease with radioisotopes conjugated to bioactive substances
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020168639A1 (en) 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
JP4583168B2 (ja) 2002-06-03 2010-11-17 ザ インスティテュート フォー システムズ バイオロジー 糖タンパク質を定量的プロテオ−ム分析する方法
US20040219609A1 (en) 2002-07-12 2004-11-04 Day Anthony G. Methods for modulating proteins not previously known as proteases
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
ES2402096T3 (es) 2003-03-26 2013-04-26 Evotec International Gmbh Uso de proteínas relacionadas con saposina para prevenir y tratar la obesidad, diabetes y/o síndrome metabólico
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
GB0318205D0 (en) 2003-08-02 2003-09-03 Albachem Ltd Synthetic method
EP1877433A2 (en) 2005-04-29 2008-01-16 (Osi) Eyetech, Inc. Vegf variants
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
CN101573371A (zh) 2006-12-29 2009-11-04 弗·哈夫曼-拉罗切有限公司 环肽类化合物的合成方法
EP3127549B1 (en) 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
US8027291B2 (en) 2007-09-27 2011-09-27 Wireless Technology Solutions Llc Method and apparatus for transmitting transport channels over a physical channel of a cellular communication system
EP2318429B1 (en) 2008-07-28 2016-04-20 Children's Medical Center Corporation Prominin-1 peptide fragments and uses thereof
EP3366695B1 (en) 2009-12-17 2021-07-07 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
EP3560509B1 (en) * 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US10646541B2 (en) * 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof

Similar Documents

Publication Publication Date Title
EP3642342A4 (en) RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA AND TREATMENT METHODS
JP2010215657A5 (enExample)
JP2016521688A5 (enExample)
PH12012501243A1 (en) Anti-c5a binding moieties with high blocking activity
JP2018198596A5 (enExample)
JP2023053978A5 (enExample)
EP4223786A3 (en) Novel anti-pad4 antibodies
EA201291147A1 (ru) Анти-c5a-антитела и способы применения антител
JP2017048194A5 (enExample)
HK1203357A1 (en) Fibroblast growth factor 21 proteins
JP2019520550A5 (enExample)
WO2017087608A8 (en) Modulators of ror-gamma
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
WO2016127179A3 (en) Immunomodulatory agents
IL222348B (en) Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate
JP2013539454A5 (enExample)
WO2015056237A3 (en) Purification of proteins
WO2017070689A3 (en) Solabegron zwitterion and uses thereof
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
WO2012022681A3 (en) Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
CR20220089A (es) Proteínas de fusión terapéuticas
EP4653537A3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
WO2014123614A3 (en) Antiviral rift valley fever virus virus peptides and methods of use
JP2021500874A5 (enExample)
UA107200C2 (uk) ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα